Study of funded drugs for genitourinary cancers
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how well newer funded cancer drugs work for people with cancers of the urinary or reproductive systems, such as bladder, prostate, or kidney cancer. Researchers want to learn about real-world outcomes based on routine care in hospitals across Spain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with a cancer of the kidney, bladder, prostate, testicle, or another part of the urinary or male reproductive system.
- You started a new drug treatment after January 1, 2023, and that drug was recently approved for funding by the Spanish health system.
- You are receiving treatment at the same hospital where you started the drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
This trial tests a new drug, PF-08634404, either by itself or together with another drug called enfortumab vedotin, for people with advanced bladder cancer that has spread. The goal is to see if these treatments can shrink tumors or slow the cancer's growth.
This study tests a new drug called enfortumab vedotin for people whose advanced urothelial cancer (bladder or urinary tract cancer) has not responded to prior immunotherapy (checkpoint inhibitors) and platinum chemotherapy. The goal is to see how safe and effective this treatment is for Indian adults.
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
This trial tests a new combination of drugs (Dato-DXd plus rilvegostomig) against standard treatments for people with high-risk, muscle-invasive bladder cancer that has been surgically removed. The goal is to see if the new treatment reduces the chance of the cancer coming back.
This study looks at how well two newer cancer drugs (enfortumab vedotin and pembrolizumab) work together for advanced upper tract urothelial carcinoma—a rare kidney cancer. Researchers are collecting information from hospitals in France to understand how patients respond and what side effects occur in everyday care.
Hear when a new Genitourinary Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.